Agreement with Terumo Australia Pty Limited for the supply of interventional cardiology products
6 January 2015
PHARMAC is pleased to announce the approval of an agreement with Terumo Australia Pty Limited (“Terumo”) for the supply of Interventional Cardiology products.
In summary, the effect of the decision is that:
- A range of Interventional Cardiology products will be listed in Section H, Part III, (‘Optional Pharmaceuticals’) of the Pharmaceutical Schedule from 1 February 2015.
- DHB hospitals can purchase these items either directly from Terumo or through a designated third party logistics provider under the national agreement.
- For the DHBs that currently use these products the national agreement will deliver savings.
Details of the decision
Following a Registration of Interest document issued in April 2014, PHARMAC has entered into an agreement with Terumo Australia Pty Ltd for the supply of a selection of Interventional Cardiology products to be listed on the Pharmaceutical Schedule. This means that DHB hospitals may purchase these products under the national agreement at the new pricing.
There are estimated savings to DHBs that currently use these products of approximately $117,000 per annum nationally, based on current usage.
The agreement is not exclusive. DHBs can continue to purchase other brands of Interventional Cardiology products at their discretion.
Educational services will be provided by Terumo to DHB personnel on appropriate use of its Interventional Cardiology products and will be arranged in a format and times as agreed with individual DHBs.
PHARMAC appreciates all of the feedback that it receives and acknowledges the time people take to respond, however no feedback was received from the Terumo consultation.
If you have any questions about this decision you can email PHARMAC at firstname.lastname@example.org or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 16 July 2020